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ABSTRACT 
Introduction: This open-label, phase 3b study 
evaluated the effectiveness and tolerability of 
oral tapentadol prolonged release (PR; 50−250 mg 
twice daily [b.i.d.]) for managing severe, chronic 
low back pain in patients responding to World 
Health Organization (WHO) step III opioids 
but tolerating treatment poorly. Equianalgesic 
ratios for tapentadol to prior strong opioids were 
calculated.
Methods: Patients rotated directly from prior 
WHO step III opioids to tapentadol. Patients 
received tapentadol PR (50−250 mg b.i.d.) 
during 5-week titration and 7-week maintenance 
periods. Tapentadol immediate release (IR) 50 mg 
(≤twice/day, ≥4 h apart) was allowed (total daily 
dose of tapentadol PR and IR ≤500 mg/day). The 
primary endpoint was responder rate 1 at week 6 
(percentage of patients with the same or less 
pain intensity [11-point numerical rating scale 
(NRS; 3-day average)] vs week −1).
Results: Responder rate 1 at week 6 (last 
observation carried forward [LOCF]) was 80.9% 
(76/94; P < 0.0001 vs. the null responder 
hypothesis rate [<60%]), resulting in a 
positive trial despite premature termination 
(136 recruited of 180 planned). Significant 
improvements from baseline in pain intensity 
and neuropathic pain symptoms were 
observed at weeks 6 and 12 with tapentadol PR 
(P < 0.05). Equianalgesic ratios were calculated 
for PR formulations alone and for PR and 
IR formulations combined for tapentadol to 
oxycodone, buprenorphine, fentanyl, morphine, 
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and hydromorphone. The prevalences of adverse 
events reported as the reason for switching to 
tapentadol (most commonly constipation and 
nausea) decreased over time.
Conclusions: Tapentadol PR (50−250 mg b.i.d.) 
provided at least comparable pain relief and 
improved tolerability versus prior strong opioids 
in patients with severe, chronic low back pain 
responding to WHO step III therapy. Conversion 
from strong opioids to tapentadol PR, with its 
two mechanisms of action, went smoothly 
considering overall effectiveness and tolerability 
outcomes. Equianalgesic ratios of tapentadol to 
oxycodone and other strong opioids were in line 
with other phase 3/3b studies.
Keywords: Chronic pain; Equianalgesic; 
Equipotency; Low back pain; Neuropathic pain; 
Opioid; Severe pain; Tapentadol
INTRODUCTION
Opioid analgesics are recommended for 
managing severe, chronic low back pain [1, 2]. 
Opioid treatment may be associated with side 
effects [3] that may be the first reason leading 
patients to discontinue opioid therapy [4, 5] 
or rotate to a different opioid. Gastrointestinal 
side effects, including nausea, constipation, 
and vomiting, are among the most commonly 
reported opioid-related side effects [4], and 
patients have reported that these are the most 
bothersome side effects associated with opioid 
treatment [6, 7]. Patients often miss or decrease 
their dose of opioid analgesic or discontinue 
opioid treatment to avoid nausea, vomiting, 
and constipation [7, 8], and physicians often 
discontinue opioid therapy because of these 
side effects [9]. In a survey [8] of 322 patients 
taking daily oral opioids and laxatives, 33% 
of patients had skipped, decreased, or stopped 
their opioid analgesic in order to obtain relief 
from opioid-induced constipation. In addition, 
opioid analgesics may not be effective for all 
patients with chronic pain, particularly patients 
with a neuropathic pain component to their 
low back pain (e.g., radiculopathy), which 
may not respond particularly well to opioid 
analgesics alone [10, 11]. Chronic therapy with 
opioid analgesics may result in development 
of tolerance, such that patients require higher 
average doses to maintain effective analgesia 
but potentially leading to more side effects [12]. 
Such tolerance development is another major 
reason why patients require opioid rotation [12]. 
The vast majority of physicians (>90%) report 
using combination treatment rather than 
monotherapy for the management of severe, 
chronic pain [13]; however, a recent Cochrane 
review by Chaparro and colleagues [14] of 
randomized controlled trials evaluating 
combination therapy for neuropathic pain 
found that although combination therapy 
offered similar or sometimes a modest gain in 
efficacy, it was often associated with higher 
incidences of side effects and discontinuations 
due to side effects. 
The centrally acting analgesic tapentadol 
has two mechanisms of action, µ-opioid 
receptor agonism and noradrenaline reuptake 
inhibition [15, 16]. Tapentadol oral prolonged 
release (PR; 100−250 mg twice daily [b.i.d.]) 
has been shown to be effective and well 
tolerated for the management of moderate 
to severe, chronic pain in previous phase 3 
studies [17−21], including randomized, double-
blind, placebo-controlled studies in patients 
with low back pain [18] and pain related to 
diabetic peripheral neuropathy [20]. A pooled 
analysis [19] of efficacy and tolerability 
results from phase 3 studies of tapentadol for 
moderate to severe, chronic osteoarthritis knee 
pain or low back pain showed that tapentadol 
PR (100−250 mg b.i.d.) provided comparable 
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analgesic efficacy to oxycodone hydrochloride 
(HCl) controlled release (20−50 mg b.i.d.) and 
that tapentadol PR was associated with superior 
gastrointestinal tolerability to oxycodone 
controlled release (based on the incidences 
of nausea, vomiting, and constipation and 
fewer discontinuations, mainly related to 
gastrointestinal and central nervous system 
adverse events [AEs]). The effectiveness of 
tapentadol PR has also been demonstrated in 
a phase 3b study of patients with severe low 
back pain with and without a neuropathic 
pain component that was not adequately 
managed with nonsteroidal anti-inflammatory 
drugs, paracetamol, or weak opioids (i.e., 
World Health Organization [WHO] step I or II 
analgesics) [22].
This multicenter, multinational, open-label 
phase 3b study included patients with severe, 
chronic low back pain who had responded 
to WHO step III opioid therapy (i.e., a low 
pain level) but showed a lack of tolerability. 
The population of patients in this study had 
chronic low back pain that had responded 
to WHO step III therapy, which differs from 
a population of patients that suffered from 
pain following washout of prior analgesics 
or a population of predefined nonresponders 
suffering from lack of efficacy of their previous 
treatment. The main objective of this trial 
was to demonstrate comparable effectiveness 
for tapentadol PR to strong opioids in strong 
opioid responders who rotated to tapentadol 
directly from WHO step III opioids; thus, 
major improvements in measures of efficacy 
were not a main objective of the trial, but were 
captured and are described here. Equianalgesic 
ratios were determined for tapentadol versus 
WHO step III analgesics, including analgesics 
other than oxycodone, which has been the 
primary active comparator during clinical trials 
evaluating tapentadol.
MATERIALS AND METHODS
All procedures followed were in accordance 
with the ethical standards of the responsible 
committee on human experimentation 
(institutional and national) and with the 
Helsinki Declaration of 1975, as revised in 2000. 
Informed consent was obtained from all patients 
for inclusion in the study.
Patient Population
This study included men and nonpregnant, 
nonlactating women who were at least 18 years 
of age and had a diagnosis of chronic low back 
pain that had been present for a minimum of 
3 months. If a radicular pain syndrome was 
present, it must have been present for a minimum 
of 3 months and stable for a minimum of 4 weeks 
prior to enrolling in the study. A WHO step III 
analgesic (in the opinion of the investigator) 
must have been required for the management of 
patients’ low back pain. Patients must have been 
taking a WHO step III analgesic for a minimum 
of 3 months prior to screening and must have 
responded to that analgesic, as indicated by an 
average pain intensity score at screening of no 
more than 5 on an 11-point numerical rating 
scale-3 (NRS-3; average pain intensity [11-point 
NRS; 0 = “no pain” to 10 = “pain as bad as you 
can imagine”] over the 3 days prior to the pain 
intensity assessment). Eligible patients had to 
report opioid-related side effects as the reason 
for a change in their analgesic, and subject 
satisfaction with their previous treatment was not 
permitted to be better than “fair” on a 5-point 
verbal rating scale (VRS; 0 = “poor,” 1 = “fair,” 
2 = “good,” 3 = “very good,” 4 = “excellent”). 
Patients were excluded from the study if they 
had any concomitant painful conditions other 
than low back pain (e.g., anatomical deformities, 
fibromyalgia), had any clinically significant 
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disease or laboratory finding, had active systemic 
or local infection, or required any painful 
procedures during the study (e.g., major surgery) 
that could confound or bias study assessments. 
Additional exclusion criteria included the 
following: a history or presence of alcohol 
or drug abuse; the presence of concomitant 
autoimmune inflammatory conditions; a history 
of or active hepatitis B or C within 3 months of 
screening; a history of HIV infection; a history 
of or laboratory values reflecting severe renal 
impairment; a history or presence of moderate or 
severe hepatic impairment; a history of seizure 
disorder or epilepsy; a history of severe traumatic 
brain injury within 15 years of screening or 
residual sequelae suggesting transient changes in 
consciousness; and a history of mild or moderate 
traumatic brain injury, stroke, transient ischemic 
attack, or brain neoplasm within 1 year of 
screening. Patients with a history of allergy or 
hypersensitivity to tapentadol or its excipients 
or contraindications to tapentadol (i.e., known 
or suspected paralytic ileus, acute or severe 
bronchial asthma or hypercapnia) were excluded 
from the study. Patients were also excluded from 
the study if they had taken monoamine oxidase 
inhibitors within 14 days prior to screening or 
nonstable doses of selective serotonin reuptake 
inhibitors (SSRIs) within 30 days prior to 
screening; SSRIs were permitted prior to and 
during the study if the dose had been stable for 
at least 30 days prior to screening and remained 
stable throughout the study.
Study Design
This was a multicenter, open-label, phase 3b 
study that included a 1-week observation 
period (on the previous WHO step III analgesic 
regimen), a 5-week titration and stabilization 
period, and a 7-week maintenance period. 
Patients stopped taking all WHO step III 
analgesics and any potential concomitant WHO 
step II analgesics at the end of the observation 
period (week −1) before they received their 
first dose of study medication. A morphine 
equivalent dose (MED) of the previous WHO step 
III analgesic(s) was determined for each patient 
using the mean total daily dose (TDD) of all 
formulations of all WHO step III opioids taken 
during the 3 days prior to the baseline visit; 
that TDD was converted to a MED supported by 
the electronic case report form. At the start of 
the titration period, patients received a starting 
dose of tapentadol PR of 50 mg, 100 mg, or 
150 mg b.i.d., depending on the MED of the 
previous WHO step III analgesic(s). A MED of 
up to 100 mg per day corresponded to a starting 
tapentadol PR dose of 50 mg b.i.d., a MED of 
101−160 mg/day corresponded to a starting 
tapentadol PR dose of 100 mg b.i.d., and a MED 
of more than 160 mg per day corresponded to 
a starting tapentadol PR dose of 150 mg b.i.d. 
In general, starting tapentadol PR doses were 
notably below the calculated MED.
At 3 days after the start of study medication 
(the time point corresponding to the interim 
visit), a first titration was permitted if needed. 
Doses of tapentadol PR were then titrated 
on a weekly basis within the dose range of 
tapentadol PR 50 mg to 250 mg b.i.d. to the 
dose that provided at least similar pain relief 
to the previous analgesic regimen, as indicated 
by a pain intensity score (11-point NRS-3) that 
was the same or lower than at baseline. Doses 
could then be titrated to achieve (or exceed) 
the following goals: at least a 1-point reduction 
in the pain intensity score (11-point NRS-3) 
from baseline and a subject satisfaction with 
treatment rating (5-point VRS) of at least “good.”
Unless patients were participating in a 
tapering substudy (described below), doses of 
WHO step I analgesics and coanalgesics and 
medications used to control opioid-related side 
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effects due to the previous analgesic regimen 
were kept stable throughout the titration and 
maintenance periods. During the titration period 
and the remainder of the study, tapentadol 
immediate release [IR] was permitted in doses of 
50 mg up to twice a day and at least 4 h apart 
for acute pain episodes due to index pain that 
had no clear cause, was related to increased 
activity or movement (incidental pain), or was 
related to end-of-dose failure (which indicated 
a need to adjust the dose of tapentadol PR) and 
for withdrawal symptoms, such as hyperalgesia, 
that might occur during the first days of the 
titration period after stopping treatment with 
the previous opioid and that were related to the 
previous opioid. Patients were not permitted 
to take combined TDD of tapentadol PR and 
tapentadol IR of more than 500 mg per day. 
The dose of tapentadol PR determined during 
the titration period was continued during the 
maintenance period.
For patients who participated in the tapering 
substudy, concomitant WHO step I analgesics 
and coanalgesics (such as anticonvulsants and 
antidepressants) were tapered and stopped, 
whenever possible, between weeks 9 and 11, 
without compromising the pain relief achieved 
on tapentadol treatment. In that substudy, 
only one analgesic or coanalgesic was tapered, 
with coanalgesics preferentially tapered over 
WHO step I analgesics. Depending on the 
available doses and the starting dose, WHO step 
I analgesics and coanalgesics were tapered at 
weekly intervals in 1−3 steps or at 5-day intervals 
in four steps. If pain intensity (NRS-3) did not 
increase following a reduction in the dose of 
the WHO step I analgesic or coanalgesic, the 
dose was further reduced until the medication 
was stopped or until the pain intensity score 
increased. The dose of the WHO step I analgesic 
or coanalgesic was returned to the previous dose 
level if the pain intensity score increased.
Effectiveness, Function, Quality of Life, and 
Tolerability Evaluations
Safety and tolerability analyses were performed 
on all patients who took one or more doses of 
study medication (the safety population). The 
pain intensity, responder rate, and equianalgesic 
analyses described in this section were performed 
for both the main analysis and per-protocol 
populations; all other effectiveness, function, 
and quality-of-life analyses were performed 
only for the main analysis population. The main 
analysis population included all patients who 
took one or more doses of study medication and 
had one or more post-baseline pain intensity 
assessments, and the per-protocol population 
(which was a subset of the main analysis 
population) included all patients who had 
received treatment through week 6 and had no 
major protocol deviations.
Patients rated their pain intensity (11-point 
NRS-3) at screening, baseline, and all subsequent 
study visits. The primary endpoint for this 
study was responder rate 1 at week 6 in the per-
protocol population, using the last observation 
carried forward (LOCF) to impute missing 
assessments; responder rate 1 was defined as 
the percentage of patients with the same or 
a lower pain intensity score compared with 
week −1 (when patients were on their previous 
WHO step III opioid). Responder rate 2 at 
week 6 (LOCF) in the per-protocol population 
was used as a secondary endpoint; responder 
rate 2 was defined as the percentage of patients 
with the same or a lower pain intensity score 
and an improvement in subject satisfaction with 
treatment of one category or more. Responder 
rates 1 and 2 were also analyzed in the main 
analysis population using observed-case analysis 
at weeks 6, 8, and 12. The following assessments 
were also evaluated as secondary endpoints: the 
change in average pain intensity from week −1 
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to weeks 6, 8, and 12; subject satisfaction with 
prior treatment (at screening and baseline) 
and study treatment (at the interim visit and 
all subsequent study visits; 5-point VRS); 
the patient global impression of change 
(PGIC) [23, 24], the clinician global impression 
of change (CGIC) [25], the EuroQol-5 Dimension 
(EQ-5D) health status questionnaire [26], the 
Short Form-36 (SF-36) health survey [27], and 
the Hospital Anxiety and Depression Scale 
(HADS) [28].
For the PGIC [23, 24] and CGIC [25], 
patients and investigators, respectively, rated 
their impression of the change in the patients’ 
overall condition since baseline using a 
7-point numerical rating scale (1 = “very much 
improved” to 7 = “very much worse”). Both the 
PGIC and CGIC were completed at the interim 
visit and all subsequent study visits. For the 
EQ-5D health status questionnaire [26], patients 
rated five dimensions of health status (mobility, 
self-care, usual activities, pain/discomfort, and 
anxiety/depression) using one of three possible 
levels (“no problems,” “some problems,” 
or “extreme problems”). The SF-36 health 
status questionnaire [27] was used to assess 
eight different dimensions of health status 
(physical activities, role physical, bodily pain, 
general health, vitality, social functioning, role 
emotional, and mental health); each of the 
eight dimensions was scored on a scale from 0 
(“poor health”) to 100 (“good health”). For the 
HADS (used to assess anxiety and depression in 
medically compromised patients) [28], patients 
rated 14 questions that assessed different 
aspects of anxiety and depression on a 4-point 
scale (0−3), with higher scores indicating more 
severe anxiety or depression symptoms [29]. The 
EQ-5D health status questionnaire, the SF-36 
health status questionnaire, and the HADS were 
completed at screening, baseline, week 1, and at 
each study visit from week 5 through week 12. 
Total daily doses of tapentadol PR and 
tapentadol IR (both separately and overall) 
were recorded throughout the study, as were 
total daily doses of WHO step II and III opioids 
taken during week −1 and average doses of WHO 
step I analgesics and coanalgesics (average daily 
dose during the last 72 h [3 days] prior to the 
respective visit) taken throughout the study.
AEs were recorded throughout the study 
for the safety population and were classified as 
treatment-emergent AEs (TEAEs; AEs that newly 
occurred after the first intake of study medication 
or that increased in intensity, frequency, or 
quality after the first intake of study drug) and 
non-TEAEs (NTEAEs; AEs occurring or present 
[including ongoing medical history] before 
starting study medication [from screening to 
the first intake of study medication]). TEAEs 
were coded using the Medical Dictionary for
Regulatory Activities (MedDRA), version 13.1.
Any TEAE that resulted in death, was life-
threatening, required hospitalization or an 
increase in the duration of hospitalization, 
resulted in long-term or significant disability or 
incapacity, was a congenital anomaly or birth 
defect, or was considered medically important 
was considered a serious TEAE. The possible 
association of AEs with any WHO step III 
analgesics and coanalgesics was documented. 
AEs were also classified according to their 
relationship to the administration of study 
medication as not related or unlikely related 
if there was evidence of no causal relationship 
to the administration of study medication and 
at least possibly related if limited evidence 
of a causal relationship was shown. The 
prevalence of AEs that were reported as the 
underlying reason for switching to tapentadol 
was compared between week −1 (on prior WHO 
step III therapy) and week 12 (on tapentadol 
PR). Standard clinical laboratory evaluations and 
vital sign measurements were performed on the 
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safety population at different time points during 
the study.
Neuropathic Pain Component Evaluations
The likelihood of a neuropathic pain component 
to low back pain was evaluated using the 
painDETECT questionnaire [30], which is a 
validated and highly sensitive screening tool 
that addresses the frequency and quality of 
neuropathic pain symptoms (seven items), pain 
patterns over time (one item), and radiating 
pain (one item). Scores for those nine items 
were summed to yield a total painDETECT score 
(possible score of 0−38) that was used to classify 
the likelihood of a neuropathic pain component 
to low back pain as “negative” (score of 0−12), 
“unclear” (score of 13−18), or “positive” (score 
of 19−38). The painDETECT questionnaire was 
completed at screening, at baseline, and at 
weeks 6, 8, and 12. Patients with a painDETECT 
“negative” score at both the screening and 
baseline visit were included in the painDETECT 
negative subset. Patients with a painDETECT 
“positive” score at screening or baseline were 
included in the painDETECT positive subset. 
Patients with a painDETECT “unclear” score at 
screening and a “negative” score at baseline (or 
vice versa) were included in the painDETECT 
unclear subset.
For patients with a painDETECT “positive” 
score at baseline, a diagnosis of lumbar 
radiculopathy was made for those who had 
typical dermatomal pain radiating beyond the 
knee towards the foot (sciatica) and evoked 
by stretching within the distribution of the 
ischiadic/femoral nerve (positive Lasègue sign), 
along with one or more of the following signs 
of root dysfunction: sensory impairment, motor 
symptoms from compression of lumbar nerve 
root (L4, L5, S1), and/or absent or diminished 
quadriceps femoris or triceps surae reflexes, 
and/or signs of root dysfunction in quantitative 
sensory testing.
For patients in the painDETECT unclear or 
positive subset, the Neuropathic Pain Symptom 
Inventory (NPSI) [31] was used to further 
evaluate the neuropathic pain component of 
their low back pain. The NPSI referred to pain 
radiating towards or into the leg in this study 
and was completed at screening, baseline, and 
at each subsequent study visit. The NPSI [31] is 
a validated measure that consists of 10 questions 
that address different qualities of spontaneous, 
ongoing or paroxysmal pain, evoked pain, and 
dysesthesia and/or paresthesia (each scored on 
an 11-point NRS [0 = “none” to 10 = “worst 
imaginable”]) and two questions that address 
the frequency and duration of pain.
Statistical Analyses
It was estimated that approximately 70% of 
the total study population would be eligible 
for inclusion in the per-protocol population. 
An estimated 125 patients in the per-protocol 
population would provide 80% power to 
differentiate between a responder rate 1 at 
week 6 of at least 60% and the null hypothesis 
responder rate 1 of less than 60%, with a 
noninferiority margin of 14.3. For responder 
rate 2, it was estimated that 125 patients in the 
per-protocol population would provide 80% 
power to differentiate between a responder 
rate 2 at week 6 of at least 60% and the null 
hypothesis responder rate 2 of less than 60%, 
with a noninferiority margin of 14.3%. An 
estimated 125 patients in the per-protocol 
population would provide 80% power to reject 
the null hypothesis that the average pain 
intensity score at week −1 was not equivalent 
to that at week 6 (i.e., the difference in means 
was ≥0.673 or farther away from 0 in the same 
direction), in favor of the alternative hypothesis 
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that responder rate 1 was at least 60% (i.e., 
tapentadol PR provided noninferior analgesia 
relative to the previous WHO step III treatment). 
Given the rejection of the null hypothesis at 
the first two steps, it was estimated that a study 
population of 178 patients would provide 80% 
power to perform the described analyses of 
responder rate 1, responder rate 2, and pain 
intensity in a step-wise manner.
The primary endpoint (responder rate 1 at 
week 6 in the per-protocol population using the 
LOCF) was evaluated using a 1-sided Chi-square 
test, as were responder rate 2 at week 6 in the 
per-protocol population (LOCF) and responder 
rates 1 and 2 at weeks 6, 8, and 12 in the main 
analysis population (observed-case analysis). A 
1-sided paired t-test was used to evaluate the 
changes from baseline in mean pain intensity 
(11-point NRS-3) at weeks 6, 8, and 12.
Weighted responses to each of the individual 
EQ-5D dimensions were used to derive an 
overall EQ-5D health status index score, with 
a possible score ranging from 0 (“dead”) to 1 
(“full health”). Weighted combinations of the 
8 SF-36 subscale scores were used to calculate 
a physical component summary score and a 
mental component summary score; the possible 
score for each summary score ranged from 0 
to 100, with higher scores indicating better 
health. For the HADS, 7 of the 14 items were 
combined to yield an anxiety subscale score 
and the remaining seven items were combined 
to yield a depression subscale score; both the 
HADS anxiety and depression subscale scores 
had a possible score of 0 to 21, with higher 
scores indicating worse symptoms of anxiety 
and depression, respectively. A one-sample 
paired t-test was used to analyze the changes 
from baseline to weeks 6, 8, and 12 in the EQ-5D 
health status index, the SF-36 subscale scores 
and summary scores, and the HADS anxiety and 
depression subscale scores.
The scores for the seven individual items 
on the painDETECT questionnaire addressing 
the frequency and quality of neuropathic pain 
symptoms and the total painDETECT score 
were summarized using descriptive statistics. 
The scores of the individual items on the NPSI 
were combined to yield the following subscores: 
burning pain, pressing pain, paroxysmal pain, 
evoked pain, and paresthesia/dysesthesia. For 
each NPSI subscore, the possible score ranged 
from 0−1, with higher scores indicating more 
severe symptoms. The NPSI subscores were 
combined to yield an overall feeling NPSI 
score (possible score, 0−1). The changes from 
baseline to weeks 6, 8, and 12 in the NPSI and 
painDETECT scores were analyzed using one-
sample paired t-tests. The neuropathic pain 
component to low back pain is challenging to 
assess [32] and may be underestimated by the 
painDETECT questionnaire; for this reason, the 
painDETECT unclear and positive subsets were 
combined for analyses of the NPSI, HADS, and 
individual painDETECT items presented herein.
For equianalgesic ratios of tapentadol to 
WHO step III opioids, the equipotent dose 
of tapentadol was defined as the mean TDD 
(average TDD during the 3 days prior to the visit) 
at which the pain intensity score was less than 
or equal to the pain intensity score at week −1. 
The average TDD of a WHO step III analgesic 
taken during the 3 days prior to the baseline 
visit was used as the corresponding mean TDD 
for equianalgesia calculations. Equianalgesic 
ratios were calculated for tapentadol PR alone 
to PR formulations of WHO step III opioids 
alone and for tapentadol PR and tapentadol IR 
combined to PR and IR formulations of WHO 
step III opioids combined. 
Separate analyses were performed for all 
effectiveness, function, and quality-of-life 
measures for the following two data sets: a 
data set that included results from weeks 9 
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through 12 for patients who participated in 
the tapering substudy (the main data set) and 
a data set that excluded results from weeks 9 
through 12 for patients who participated in the 
tapering substudy. Results of all effectiveness, 
function, and quality-of-life measures using 
the data set that excluded results from weeks 9 
through 12 for patients who participated in the 
tapering substudy were evaluated using both 
observed-case analysis and LOCF for imputing 
missing assessments. WHO step I analgesics 
and coanalgesics were tapered in the substudy, 
which could potentially have resulted in pain 
peaks that might affect effectiveness, function, 
and quality-of-life analyses. In general, similar 
results were observed for the main data set 
(which included results from weeks 9 through 
12 for patients who participated in the tapering 
substudy) and the data set that excluded results 
from weeks 9 through 12 for patients who 
participated in the tapering substudy. Unless 
otherwise specified, the results presented here 
are for the main data set (which included results 
from weeks 9 through 12 for patients who 
participated in the tapering substudy) using 
observed-case analysis. Results for the data set 
that excluded results from weeks 9 through 12 
for patients who participated in the tapering 
substudy using observed-case analysis and LOCF 
are summarized in the Appendix.
RESULTS
Patients
This study was prematurely terminated due to 
slow recruitment and study drug shortages; as 
a result, the numbers of patients in the study 
populations were lower than initially planned. A 
total of 125 patients were included in the safety 
population, 123 patients were included in the 
main analysis population, and 94 patients were 
included in the per-protocol population. In the 
safety population, 37.6% (47/125) of patients 
were included in the painDETECT negative subset 
and 62.4% (78/125) of patients were included 
in the painDETECT unclear/positive subset 
(Table 1). Fifty-one patients in the painDETECT 
positive subset underwent additional diagnostic 
testing; based on this testing, 58.8% (30/51) of 
these patients had a positive diagnosis of lumbar 
radiculopathy at screening or baseline.
Baseline and demographic characteristics 
for the overall safety population and by 
baseline painDETECT subset are summarized 
in Table 2, and the history of low back pain is 
summarized in Table 3. Patients in this study 
had a mean ongoing history of low back pain 
of 12.4 years. Thus, this patient population is 
representative of individuals with a long-term 
history of low back pain, with a history of 
Table 1 Baseline painDETECT classicationsa
Baseline Safety Main analysis Per-protocol Tapering 
painDETECT population population population substudy 
classication, n (%) (n = 125) (n = 123) (n = 94) (n = 23)
Negative 47 (37.6) 47 (38.2) 33 (35.1) 6 (26.1)
Unclear 26 (20.8) 25 (20.3) 19 (20.2) 6 (26.1)
Positive 52 (41.6) 51 (41.5) 42 (44.7) 11 (47.8)
Unclear/positive 78 (62.4) 76 (61.8) 61 (64.9) 17 (73.9)
a Baseline painDETECT classications were based on the total painDETECT score (possible score, 0−38); the likelihood of 
a neuropathic pain component to low back pain was classied as “negative” (score of 0−12), “unclear” (score of 13−18), or 
“positive” (score of 19−38)
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multiple previous analgesic regimens and a high 
degree of suffering, particularly for those with a 
neuropathic pain component.
During week −1, all but two patients took 
WHO step III analgesics. For the two patients 
who did not receive WHO step III pretreatment, 
the absence of pretreatment was detected only 
after the patients had enrolled and entered 
the study; both patients were considered 
major protocol violators. The most commonly 
used WHO step III analgesics during week −1 
included oral oxycodone, transdermal fentanyl, 
transdermal or IR (sublingual) buprenorphine, 
and oral morphine (Table 4). A total of 21.6% 
(27/125) of patients were taking WHO step II 
analgesics during week −1. The WHO step II 
Table 2 Baseline and demographic characteristics (safety population)
Characteristic painDETECT  painDETECT Total 
  negative unclear/positive (n = 125)
  (n = 47) (n = 78) 
Mean (SD) age, years 59.9 (11.57) 55.3 (11.99) 57.1 (12.00)
Gender, n (%)   
 Female 30 (63.8) 46 (59.0) 76 (60.8)
 Male 17 (36.2) 32 (41.0) 49 (39.2)
Mean (SD) BMI, kg/m2 28.6 (4.84) 28.2 (5.53) 28.3 (5.27)
Race, n (%)   
 White 47 (100.0) 77 (98.7) 124 (99.2)
 Asian 0 1 (1.3) 1 (0.8)
BMI body mass index, SD standard deviation 
Table 3 History of low back pain (safety population)
Parameter painDETECT painDETECT Total
  negative unclear/positive (n = 124)
  (n = 47) (n = 77)
Mean (SD) duration of pain, years 13.8 (11.30) 11.5 (10.91) 12.4 (11.07)
Mean (SD) time to rst pain-related  
consultation, months 19.1 (44.79) 6.6 (23.92) 11.3 (33.78)
Mean (SD) number of doctors visited  
since pain started 4.8 (3.14) 5.8 (5.49) 5.4 (4.75)
Mean (SD) number of consultations  
within 3 months 2.5 (1.91) 3.3 (5.20) 3.0 (4.27)
Hospitalization due to pain, n (%) 23 (48.9) 54 (69.2) 77 (61.6)
Mean (SD) number of analgesic regimens  
since pain starteda 5.3 (3.61) 6.4 (5.10) 6.0 (4.61)
Mean (SD) times of being o work due  
to pain per yearb 12.3 (32.52) 3.4 (5.30) 6.9 (20.51)
SD standard deviation
a painDETECT negative, n = 46; painDETECT unclear/positive, n = 76; total, n = 122
b painDETECT negative, n = 9; painDETECT unclear/positive, n = 14; total, n = 23
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analgesics taken concomitantly during week −1 
were tramadol (17.6% [22/125]); a fixed-dose 
combination of tramadol/paracetamol 
(2.4% [3/125]); a fixed-dose combination of 
codeine/paracetamol (0.8% [1/125]); and a fixed-
dose combination of tilidine HCl/naloxone 
HCl (0.8% [1/125]). The TDDs of WHO step III 
opioids that patients were taking at baseline 
were converted to MEDs, which are summarized 
in Table 5. The starting doses of tapentadol 
for patients taking TDDs of WHO step III 
opioids in all three MED cohorts (≤100 mg/day, 
101−160 mg/day, >160 mg/day) were generally 
lower than the MEDs (in some cases, more 
than 50% lower). Week −1 MED cohort data 
were not available for five patients in the safety 
population; those five patients did not have 
proper documentation of analgesic medication 
in their diaries, which was used to determine 
starting doses, so the starting doses for those 
patients were determined by the investigator. 
Three of those patients took starting doses of 
tapentadol PR of 100 mg b.i.d. (corresponding 
to the MED cohort of 101−160 mg/day), one 
patient took a starting dose of tapentadol PR of 
50 mg b.i.d. (corresponding to the MED cohort 
of ≤100 mg/day), and one patient received study 
medication but was lost to follow-up. 
During the study, 83.2% (104/125) of patients 
took concomitant analgesics or coanalgesics. 
A total of 63.2% (79/125) of patients took 
concomitant WHO step I analgesics; the most 
commonly used WHO step I analgesics during 
the study included paracetamol (22.4% [28/125]), 
meloxicam (11.2% [14/125]), metamizole 
(dipyrone; 11.2% [14/125]), diclofenac (9.6% 
[12/125]), and ibuprofen (8.8% [11/125]). 
Concomitant coanalgesics were used by 54.4% 
(68/125) of patients during the study, and the 
most commonly used coanalgesics during the 
study included pregabalin (17.6% [22/125]), 
amitriptyline (12.8% [16/125]), gabapentin (10.4% 
[13/125]), and clonazepam (8.8% [11/125]). The 
use of WHO step II and WHO step III analgesics 
(which were prohibited according to the study 
protocol) was reported for 3.2% (4/125) and 
5.6% (7/125) of patients, respectively; two of the 
patients who took WHO step II or III analgesics 
were excluded from the per-protocol population 
due to major protocol deviations and one of 
the patients who took WHO step III analgesics 
discontinued the study at visit 6.
Table 4 WHO Step III analgesics taken during week −1 
(safety population)
WHO step III analgesic, n (%)a Total






Naloxone HCl, oxycodone HCl 2 (1.6)
Levomethadone 1 (0.8)
Methadone HCl 1 (0.8)
HCl hydrochloride, WHO World Health Organization
a Fentanyl was administered transdermally. Buprenorphine 
was administered transdermally or as an immediate-release 
formulation (sublingually). All other WHO step III 
opioids were administered orally
b Two patients took no WHO step III analgesics during 
week −1
Table 5 MEDs of TDDs of previous WHO step III 
opioids at baseline (safety population)
Average MEDa, n (%) Total
 (n = 120)b
≤100 mg/day 68 (56.7)
101−160 mg/day 29 (24.2)
>160 mg/day 23 (19.2)
MED morphine equivalent dose, TDD total daily dose, 
WHO World Health Organization
a Includes all formulations of all opioids taken
b e MED cohort was unknown for ve patients in the 
safety population
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Overall, 25.6% (32/125) of patients 
discontinued the study prematurely. The 
reasons for premature study discontinuation 
included adverse events (16.0% [20/125]), 
withdrawal of consent for any reason (4.0% 
[5/125]), a lack of efficacy (4.0% [5/125]), study 
medication noncompliance (0.8% [1/125]), 
or unknown reasons (0.8% [1/125]). The one 
patient who discontinued because of safety 
reasons not related to the study medication had 
a serious TEAE of myocardial infarction that was 
considered by the investigator to be not related 
to treatment with tapentadol.
Effectiveness, Function, and Quality of Life
Unless otherwise specified, effectiveness, 
function, and quality-of-life results presented 
here are for the main data set (which included 
results from weeks 9 through 12 for patients 
who participated in the tapering substudy) 
using observed-case analysis. For the primary 
endpoint, responder rate 1 (LOCF) in the per-
protocol population was 80.9% (76/94) at 
week 6 and was significantly different from the 
null hypothesis responder rate of less than 60% 
(P < 0.0001), indicating that the effectiveness of 
tapentadol PR was noninferior to previous WHO 
step III opioids. Responder rate 2 (LOCF) in the 
per-protocol population was 66.0% (62/94) at 
week 6 and was significantly different from the 
null hypothesis responder rate of less than 60% 
(P < 0.0001). In the main analysis population, 
responder rate 1 increased from baseline to week 4 
(78.6% [81/103]) and remained relatively steady 
during the remainder of the study; responder 
rate 1 was 80.4% (82/102) at week 6, 82.3% 
(79/96) at week 8, and 81.7% (76/93) at week 12. 
For patients in the painDETECT negative and 
unclear/positive subsets, respectively, responder 
rate 1 was 81.1% (30/37) and 80.0% (52/65) at 
week 6, 94.1% (32/34) and 75.8% (47/62) at 
week 8, and 91.2% (31/34) and 76.3% (45/59) at 
week 12. Responder rate 2 in the main analysis 
population was 63.7% (65/102) at week 6, 74.0% 
(71/96) at week 8, and 74.2% (69/93) at week 12. 
For patients in the painDETECT negative and 
unclear/positive subsets, respectively, responder 
rate 2 was 62.2% (23/37) and 64.6% (42/65) at 
week 6, 79.4% (27/34) and 71.0% (44/62) at 
week 8, and 73.5% (25/34) and 74.6% (44/59) 
at week 12. The mean (SD) pain intensity 
score at baseline was 4.8 (0.75); pain relief 
was maintained during the initial switch to 
tapentadol PR. Significant decreases in mean 
(SD) pain intensity scores were observed with 
continued tapentadol PR treatment, with a 
change of −0.9 (1.89) by week 6, −1.1 (1.91) by 
week 8, and −1.3 (2.10) by week 12 (P < 0.0001 
for the change from baseline for all comparisons; 
Fig. 1). Similar decreases in pain intensity were 
reported for patients diagnosed with lumbar 
radiculopathy (n = 30); mean (SD) pain intensity 
for pain radiating towards or into the leg was 4.9 
(1.31) at baseline and decreased by −1.4 (2.31) 
by week 6, −1.5 (2.58) by week 8, and −1.2 (2.59) 
by week 12.
At baseline, none of the patients in the main 
analysis population rated their satisfaction with 
their previous WHO step III analgesic treatment 
as “good,” “very good,” or “excellent.” The 
percentage of patients rating their satisfaction 
with tapentadol PR treatment as “good,” “very 
good,” or “excellent” was 72.5% (74/102) at 
week 6 and 82.8% (77/93) at week 12 (Fig. 2). 
On the PGIC, the percentage of patients who 
reported that their overall status was “minimally 
improved,” “much improved,” or “very much 
improved” since starting study treatment was 
79.4% (81/102) at week 6, 83.3% (80/96) at 
week 8, and 87.1% (81/93) at week 12 (Fig. 3). 
On the CGIC, a rating of “minimally improved,” 
“much improved,” or “very much improved” for 
the patients’ overall status since starting study 
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Fig. 1  Mean pain intensity (NRS-3) over time (main analysis population; observed-case analysis).a BL baseline, IN interim, 
NRS-3 numerical rating scale-3, SC screening, SD standard deviation, W week. a SD: SC, 0.80; BL, 0.75; W1, 1.68; W2, 
1.63; W3, 1.51; W4, 1.56; W5, 1.69; W6, 1.77; W7, 1.82; W8, 1.86; W9, 1.89; W10, 1.90; W11, 1.89; W12, 1.97. 




































Fig. 2  Subject satisfaction with treatment ratings at 
baseline, week 6, and week 12 (main analysis population; 


















































Fig. 3  PGIC ratings at weeks 6, 8, and 12 (main analysis 
population; observed-case analysis).a PGIC patient global 
impression of change. a Percentages may not total 100.0% 
because of rounding
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treatment was reported by 80.4% (82/102) 
of investigators at week 6, 84.4% (81/96) of 
investigators at week 8, and 87.1% (81/93) of 
investigators at week 12.
Significant increases were observed in 
the mean EQ-5D health status index score 
from baseline to week 6 (mean [SD] change 
from baseline, 0.15 [0.266]), from baseline 
to week 8 (0.16 [0.294]), and from baseline 
to week 12 (0.16 [0.257]; P < 0.0001 for all 
comparisons). At week 6, significant increases 
from baseline were observed in all mean SF-36 
domain scores (P < 0.05 for all comparisons), 
except for the role emotional score (Fig. 4). 
Significant increases from baseline were observed 
in all mean SF-36 domain scores at week 12 
(P < 0.05 for all comparisons; Fig. 4). The mean 
physical component summary score increased 
significantly from baseline to week 6 (mean [SD] 
change from baseline, 4.3 [7.88]) and week 12 
(3.8 [7.91]; P < 0.0001 for both comparisons). 
The mean (SD) mental component summary 
score increased significantly from baseline to 
week 12 (mean [SD] change from baseline, 5.1 
[10.62]; P < 0.0001), but not from baseline to 




















































































Week 12 (n = 93)b
Fig. 4  Mean changes in SF-36 domain scores from baseline to week 6 and week 12 (main analysis population; observed-case 
analysis). SD standard deviation, SF-36 Short Form-36. a SD: Physical functioning, 18.65; role - physical, 28.89; bodily pain, 
20.00; general health, 15.10; vitality, 17.44; social functioning, 24.47; role - emotional, 42.26; mental health, 16.73. 
b SD: Physical functioning, 19.96; role - physical, 31.65; bodily pain, 22.84; general health, 14.98; vitality, 21.03; social 
functioning, 27.07; role - emotional, 43.06; mental health, 17.70. c n = 98. d n = 101. e n = 100. f n = 91. * P < 0.05
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In the main analysis population, the mean 
(SD) HADS anxiety subscale score was 7.5 (4.23) 
at baseline and decreased significantly from 
baseline to weeks 6, 8, and 12 (P < 0.005 for all 
comparisons; Fig. 5a). Significant decreases were 
also observed in the mean (SD) HADS depression 
subscale score from baseline (7.9 [4.54]) to 
weeks 6, 8, and 12 (P < 0.005 for all comparisons; 
Fig. 5b). At baseline, the mean (SD) HADS 
anxiety and depression subscale scores were 
higher (and clinically relevant) for patients 
in the painDETECT unclear/positive group 
(8.5 [3.96] and 8.9 [4.33], respectively; scores of 
≥8 are considered to indicate the likely presence 
of anxiety or depression [29]) than for patients 
in the painDETECT negative group (5.9 [4.21] 
and 6.2 [4.40], respectively; not in line with a 
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Fig. 5  Mean HADS (a) anxiety and (b) depression subscale scores for the overall population and by painDETECT subset 
(observed-case analysis; main analysis population) (continued on next page). BL baseline, HADS Hospital Anxiety and 
Depression Scale, SD standard deviation, W week. a SD: painDETECT negative: BL, 4.21; W1, 3.93; W5, 3.82; W6, 3.69; 
W7, 3.43; W8, 3.40; W9, 3.43; W10, 3.57; W11, 3.12; W12, 3.26; painDETECT unclear/positive: BL, 3.96; W1, 4.22; 
W5, 3.71; W6, 4.02; W7, 3.82; W8, 4.16; W9, 4.16; W10, 4.30; W11, 4.08; W12, 4.01; total: BL, 4.23; W1, 4.18; W5, 
3.90; W6, 4.03; W7, 3.80; W8, 4.05; W9, 4.15; W10, 4.18; W11, 3.95; W12, 4.06. b SD: painDETECT negative: BL, 
4.40; W1, 4.70; W5, 3.65; W6, 3.46; W7, 3.49; W8, 3.62; W9, 3.66; W10, 3.76; W11, 3.98; W12, 3.42; painDETECT 
unclear/positive: BL, 4.33; W1, 4.18; W5, 3.82; W6, 4.14; W7, 4.04; W8, 4.53; W9, 4.61; W10, 4.92; W11, 4.46; W12, 
4.67; total: BL, 4.54; W1, 4.46; W5, 3.99; W6, 4.17; W7, 4.02; W8, 4.42; W9, 4.54; W10, 4.73; W11, 4.49; W12, 4.57. 
* P < 0.05 for the change from baseline
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painDETECT unclear/positive group, significant 
decreases from baseline were observed in the 
mean HADS anxiety subscale score at weeks 6, 
8, and 12 (P < 0.001 for all comparisons) and 
in the mean HADS depression subscale score at 
weeks 6 and 8 (P < 0.01 for both comparisons; 
Fig. 5). For patients in the painDETECT negative 
group, significant decreases from baseline 
were observed in the mean HADS anxiety and 
depression subscale scores at weeks 8 and 12 
(P < 0.05 for all comparisons; Fig. 5), but not at 
week 6.
Responder rates, mean pain intensity scores, 
subject satisfaction with treatment ratings, PGIC 
and CGIC ratings, EQ-5D health status index 
scores, SF-36 domain and summary scores, and 
HADS anxiety and depression subscale scores were 
comparable whether results from weeks 9 through 
12 were included or excluded for patients who 
participated in the tapering substudy (Appendix 
Tables A1–A7). Results for these effectiveness, 
function, and quality-of-life measures for the data 
set that excluded results from weeks 9 through 
12 for patients who participated in the tapering 
substudy and using LOCF are also presented in 
Appendix Tables A1–A7.
Treatment Exposure and Equianalgesia to 
Prior WHO Step III Opioids
Table 6 shows the number of dose adjustments 
required to reach the minimum target of 
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titration at visit 6 by responder status and 
by painDETECT subset. In the main analysis 
population, approximately two-thirds of 
patients required no dose adjustment to reach 
the minimum target of titration (i.e., pain 
intensity score [11-point NRS-3] that was the 
same or lower than at baseline) by visit 6. For 
responders (based on the primary endpoint 
responder rate 1 analysis), no tapentadol PR 
dose adjustment was required by approximately 
three-quarters of patients to reach the minimum 
target of titration by visit 6. The mean (SD) 
TDD of tapentadol PR at week 6 (after doses 
had stabilized) was 322.8 (120.73) mg, and 
the mean (SD) TDD of tapentadol IR at week 6 
was 24.6 (32.96) mg. The dose distribution of 
tapentadol PR at week 6 is described in Table 7. 
Equianalgesic ratios for tapentadol PR alone to 
PR formulations of oral oxycodone, transdermal 
buprenorphine, transdermal fentanyl, oral 
morphine, and oral hydromorphone are 
summarized in Table 8, along with equianalgesic 
ratios for tapentadol PR plus tapentadol IR to 
PR and IR formulations of the same five WHO 
step III opioids (oral oxycodone, transdermal 
[PR] and oral [sublingual; IR] buprenorphine, 
transdermal fentanyl, oral morphine, and oral 
hydromorphone). In the higher MED dose ranges 
(particularly beyond the equianalgesic dose ratio 
of the maximum daily dose [500 mg/day] of 
tapentadol), equianalgesic ratios decreased in 
favor of tapentadol (Table 9).
Neuropathic Pain Component
Significant decreases from baseline were 
shown in the mean (SD) total painDETECT 
score at weeks 6, 8, and 12 in the painDETECT 
Table 6  Number of dose adjustments to reach the minimum target of titration at visit 6 (main analysis population) in 
responders and the overall population (responders/nonresponders) by painDETECT categorya
Number of dose Respondersb Overall population 
adjustments, n (%) (n = 94) painDETECT painDETECT Total 
  negative (n = 47) unclear/positive (n = 76) (n = 123)
0 70 (74.5) 31 (66.0) 49 (64.5) 80 (65.0)
1 13 (13.8) 8 (17.0) 12 (15.8) 20 (16.3)
2 7 (7.4) 6 (12.8) 7 (9.2) 13 (10.6)
3 3 (3.2) 2 (4.3) 7 (9.2) 9 (7.3)
4 1 (1.1) 0 1 (1.3) 1 (0.8)
a e minimum target of titration was dened as achieving at least similar ecacy compared to the previous treatment (i.e., 
pain intensity score [11-point numerical rating scale-3] that was the same or lower than at baseline)
b Based on the primary endpoint responder rate 1 analysis
Table 7  Doses of tapentadol PR and tapentadol IR at 
week 6 (main analysis population)
Dose, n (%) Total
  (n = 101)
Tapentadol PR 
 50 mg b.i.d. 9 (8.9)
 100 mg b.i.d. 22 (21.8)
 150 mg b.i.d. 22 (21.8)
 200 mg b.i.d. 33 (32.7)
 250 mg b.i.d. 15 (14.9)
Tapentadol IR 
 None 55 (54.5)
 >0 to <50 mg 14 (13.9)
 50 mg 19 (18.8)
 >50 to <100 mg 3 (3.0)
 100 mg 10 (9.9)
b.i.d. twice daily, IR immediate release, PR prolonged 
release 
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unclear and positive subsets (P < 0.005 for all 
comparisons; Fig. 6). Patients with a painDETECT 
positive score at baseline had an unclear score 
by week 6 and for the remainder of the study, 
and patients with a painDETECT unclear score 
at baseline had a negative score by week 6 and 
for the remainder of the study. In the baseline 
painDETECT unclear/positive subset, significant 
improvements from baseline to week 6 and 
from baseline to week 12 were observed in all 
individual painDETECT item scores (P < 0.05 
for all comparisons; Table 10), and the NPSI 
paroxysmal pain, pressing pain, evoked pain, 
burning pain, and paresthesia/dysesthesia 
subscores and the NPSI overall feeling score 
improved significantly from baseline to 
week 6 and from baseline to week 12 (P < 0.05 
for all comparisons; Table 11a). On the NPSI, 
the number of pain attacks that patients in the 
painDETECT unclear/positive subset reported 
in a 24-h period (Table 11b) decreased over the 
course of the study.
Similar mean NPSI scores, numbers of 
pain attacks in a 24-h period (on the NPSI), 
and amounts of time that patients reported 
spontaneous pain in a 24-h period (on the NPSI) 
were observed at week 12 whether results from 
weeks 9 through 12 for patients who participated 
in the tapering substudy were included or 
excluded (Appendix Table A8). Improvements in 
NPSI results were consistent at weeks 6 and 12 
whether LOCF or no imputation method was 
used (Appendix Table A8).
Tapering Substudy
Overall, 87.0% (20/23) of patients reduced their 
dose of WHO step I analgesics or coanalgesics 
in the course of the tapering substudy, and 
65.2% (15/23) of patients completely stopped 
Table 8  Equianalgesic ratios of tapentadol to WHO step III opioids (main analysis population)a
WHO step III opioida n PR formulations PR and IR formulations
Oxycodone  35b 4.3:1 5.3:1
Buprenorphine  24c 170.4:1 210.0:1
Fentanyl 22 223.9:1 250.7:1
Morphine 14 2.9:1 3.0:1
Hydromorphone 8 8.3:1 10.5:1
IR immediate release, PR prolonged release, WHO World Health Organization
a Fentanyl was administered transdermally. Buprenorphine was administered transdermally or as an IR formulation 
(sublingually). All other WHO step III opioids were administered orally
b PR formulations, n = 34
c PR formulations, n = 21
Table 9  Equianalgesic ratios of tapentadol to prior WHO step III opioids by MED of prior therapy (main analysis 
population)
Average MEDa n PR formulations PR and IR formulations
≤100 mg/day 60a 3.0:1 3.6:1
101−160 mg/day 27 1.9:1 2.3:1
>160 mg/day 18 1.4:1 1.6:1
IR immediate release, MED morphine equivalent dose, PR prolonged release, WHO World Health Organization
aPR formulations, n = 56
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their WHO step I analgesic or coanalgesic doses 
(Table 12). A total of 82.4% (14/17) of patients 
reduced their dose of coanalgesics during 
the substudy, and 65.2% (15/23) of patients 
completely stopped their WHO step I analgesic 
or coanalgesic doses (Table 12). All patients 
(n = 6) who were tapering their dose of WHO 
step I analgesics during the substudy completely 
stopped their WHO step I analgesic doses 
(Table 12). The WHO step I analgesics reduced 
in the substudy included diclofenac sodium, 
ketoprofen, and paracetamol; the coanalgesics 
reduced in substudy A included amitriptyline, 
duloxetine, gabapentin, pregabalin, tolperisone, 
Table 10  Mean (SD) painDETECT individual item scores in the baseline painDETECT unclear/positive subsets 
(observed-case analysis; main analysis population)
Mean (SD) painDETECT score Baseline Week 6 Week 12
 (n = 74) (n = 65) (n = 59)
Burning sensation  2.5 (1.40) 2.0 (1.49)* 1.8 (1.44)*
Tingling or prickling sensation  2.9 (1.08) 2.2 (1.33)* 2.1 (1.39)*
Light touching painful 1.7 (1.18) 1.2 (1.21)* 1.0 (1.31)*
Sudden pain attacks 3.1 (1.11) 2.0 (1.36)* 1.9 (1.57)*
Cold or heat occasionally painful 1.9 (1.30) 1.5 (1.47)* 1.5 (1.45)*
Sensation of numbness 2.8 (1.11) 2.4 (1.04)* 2.2 (1.26)*
Slight pressure triggers pain 2.8 (1.21) 2.5 (1.47)* 2.1 (1.51)*
SD standard deviation
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Fig. 6  Mean painDETECT scores over time by baseline painDETECT subset (observed-case analysis; main analysis 
population).a BL baseline, SD standard deviation, W week. a SD: painDETECT negative: BL, 3.90; W6, 4.18; W8, 4.20; 
W12, 4.85; painDETECT unclear: BL, 2.39; W6, 4.75; W8, 5.52; W12, 5.43; painDETECT positive: BL, 3.39; W6, 5.95; 
W8, 6.63; W12, 7.17. b BL, n = 44; W6, n = 35; W12, n = 33. c BL, n = 24; W6, n = 20; W12, n = 19. d BL, n = 50; W6, 
n = 45; W12, n = 40. * P < 0.005 for the change from baseline
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and flupirtine. Of the eight patients who 
reduced their dose of pregabalin, four patients 
tapered their dose completely, dose reductions 
of 75% and 50% were achieved by one patient 
each, and two patients did not reduce their dose. 
Of the three patients who reduced their dose 
of gabapentin, a complete dose reduction was 
achieved by two patients, and a dose reduction 
of 33.3% was achieved by the remaining patient. 
Responder rate 1 was 82.6% (19/23) at week 6, 
78.3% (18/23) at week 8, and 87.0% (20/23) at 
week 12; responder rate 2 was 69.6% (16/23) 
at week 6, 73.9% (17/23) at week 8, and 82.6% 
(19/23) at week 12. Significant decreases were 
observed in the mean (SD) pain intensity score 
from baseline (5.0 [0.21]) to week 6 (mean [SD] 
change from baseline, −1.3 [2.14]; P = 0.0079), 
week 8 (−1.4 [2.13]; P = 0.0038), and week 12 
(−1.9 [2.23]; P = 0.0005).
Safety and Tolerability
All patients reported at least one NTEAE. Of 
the 713 NTEAEs recorded, 708 were related to 
ongoing medical conditions or diseases present 
at the screening visit; the remaining five were 
newly occurring NTEAEs that were reported 
during week −1. The most common (frequency 
≥5%) NTEAEs reported were constipation (9.1% 
[65/713]), hypertension (6.5% [46/713]), and 
nausea (6.0% [43/713]).
A total of 68.0% (85/125) of patients reported 
at least one TEAE. A total of 67.3% (245/364) of 
the 364 TEAEs reported from week 1 to week 12 
Table 11  NPSI results in the baseline painDETECT unclear/positive subset: (a) mean (SD) NPSI overall feeling and 
subscores, (b) total number of pain attacks within the past 24 h (observed-case analysis; main analysis population)
a) Overall feeling and subscores
Mean (SD) NPSI score Baseline Week 6 Week 12
 (n = 71) (n = 61) (n = 56)
Overall feeling score 0.41 (0.158)a 0.30 (0.178)b,* 0.28 (0.211)*
Burning pain subscore 0.41 (0.284) 0.32 (0.273)* 0.27 (0.281)*
Pressing pain subscore 0.41 (0.230)a 0.32 (0.229)b,* 0.30 (0.235)*
Paroxysmal pain subscore 0.42 (0.221) 0.27 (0.231)* 0.25 (0.255)*
Evoked pain subscore 0.39 (0.216) 0.27 (0.212)* 0.27 (0.252)*
Paresthesia/dysesthesia subscore 0.42 (0.233) 0.30 (0.210)* 0.30 (0.239)*
b) Number of pain attacks
Number of pain attacks during the past 24 h, n (%) Baseline Week 6 Week 12
 (n = 76) (n = 65) (n = 59)
>20 attacks 6 (7.9) 5 (7.7) 4 (6.8)
11−20 attacks 10 (13.2) 10 (15.4) 7 (11.9)
6−10 attacks 19 (25.0) 12 (18.5) 11 (18.6)
1−5 attacks 28 (36.8) 20 (30.8) 14 (23.7)
No attacks 8 (10.5) 14 (21.5) 20 (33.9)
Missing 5 (6.6) 4 (6.2) 3 (5.1)
NPSI Neuropathic Pain Symptom Inventory, SD standard deviation
a n = 69
b n = 60
* P < 0.05 for the change from baseline
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were classified as at least possibly related to 
study medication. A total of 78.6% (286/364) 
of the reported TEAEs were of mild-to-moderate 
intensity. The TEAEs that were reported by at 
least 5% of patients are summarized in Table 13. 
Drug withdrawal syndrome, which was likely due 
to physical dependence related to the previous 
opioid analgesic, occurred in 20.8% (26/125) of 
patients. All but one case of drug withdrawal 
syndrome occurred at the switch from prior 
WHO step III therapy between weeks 0 and 6; 
one patient reported additional drug withdrawal 
syndrome at the end of the study. A total of 50% 
(13/26) of cases of drug withdrawal were reported 
at a single study site. The prevalence of the AEs 
that patients reported as the underlying reason 
for switching to tapentadol generally decreased 
from week −1 (on WHO step III opioids) to 
week 12 (on tapentadol PR; Fig. 7); the most 
common AEs reported as the underlying reason 
for switching to tapentadol (incidence ≥10% 
at week −1) were constipation, nausea, fatigue, 
and somnolence. Serious TEAEs were reported 
for 8.8% (11/125) of patients. Twelve of the 
19 serious TEAEs reported were considered by 
the investigator to be unlikely or not related 
to study treatment. One additional patient 
experienced toxic hepatitis that was considered 
by the investigator to be probably related to 
study treatment and occurred 1 day after the 
end of study treatment; this TEAE was not 
included in the count of serious TEAEs. A total 
of 14.4% (18/125) of patients experienced TEAEs 
that led to study discontinuation; 15 of these 
18 TEAEs were considered by the investigator 
to be related to study treatment. TEAEs leading 
to study discontinuation (incidence ≥1%) 
included nausea (3.2% [4/125]), vomiting (2.4% 
[3/125]), drug withdrawal syndrome (1.6% 
[2/125]), headache (1.6% [2/125]), dizziness 
(1.6% [2/125]), disturbance in attention (1.6% 
[2/125]), and vertigo (1.6% [2/125]).
Vital sign parameters, laboratory values, 
or physical examination findings showed no 
clinically relevant changes over the course of 
study treatment.
DISCUSSION
Results of this study were positive and indicated 
that tapentadol PR (50−250 mg b.i.d.) provided at 
least comparable effectiveness to previous WHO 
step III opioid analgesics for the management of 
Table 12 Percent reduction of analgesic or coanalgesic 
medication during the tapering substudy (substudy 
subset)
Percent reduction of analgesic or Total 
coanalgesic, n (%) 
Any analgesic or coanalgesic (%) (n = 23)
 100.0 15 (65.2)
 75.0 1 (4.3)
 50.0 2 (8.7)
 33.3 2 (8.7)
 0 3 (13.0)
WHO step I analgesics (%) (n = 6)
 100.0 6 (100.0)
Coanalgesics (%) (n = 17)
 100.0 9 (52.9)
 75.0 1 (5.9)
 50.0 2 (11.8)
 33.3 2 (11.8)
 0 3 (17.6)
Antidepressants (%) (n = 4)
 100.0 2 (50.0)
 50.0 1 (25.0)
 0 1 (25.0)
Anticonvulsants (%) (n = 11)
 100.0 6 (54.5)
 75.0 1 (9.1)
 50.0 1 (9.1)
 33.3 1 (9.1)
 0 2 (18.2)
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Week 12 (on tapentadol PR; n = 93)
Table 13  TEAEs reported by at least 5% of patients (safety population)a,b
System organ class, n (%) Total
 Preferred term, n (%) (n = 125)
Gastrointestinal disorders 46 (36.8)
 Nausea 19 (15.2)
 Constipation 15 (12.0)
 Diarrhea 13 (10.4)
 Dry mouth 8 (6.4)
 Upper abdominal pain 7 (5.6)
General disorders and administration site conditions 41 (32.8)
 Drug withdrawal syndrome 26 (20.8)
 Fatigue 13 (10.4)
Nervous system disorders 40 (32.0)
 Headache 18 (14.4)
 Dizziness 16 (12.8)
Psychiatric disorders 31 (24.8)
 Insomnia 16 (12.8)
Skin and subcutaneous tissue disorders 16 (12.8)
 Hyperhidrosis 10 (8.0)
TEAE treatment-emergent adverse event
a A patient may have ndings in >1 category
b TEAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA), version 13.1
Fig. 7 Prevalence of AEs (≥2%) reported as the underlying reason for switching to tapentadol at week −1 and at week 12 
(safety population).a AE adverse event, PR prolonged release, WHO World Health Organization. a e prevalence of these 
AEs was summarized during week −1 (the week prior to titration when patients were still on WHO step III treatment) and 
during week 12 (the nal week of tapentadol PR treatment)
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severe, chronic low back pain in patients who had 
responded to WHO step III opioids but showed 
a lack of tolerability. After 4 weeks of tapentadol 
PR treatment and through the remainder of 
the study, approximately 80% of patients had 
the same or less pain intensity compared with 
week −1 (on prior WHO step III therapy). Based 
on mean pain intensity scores (NRS-3), pain 
relief was maintained after switching from WHO 
step III opioids to tapentadol PR treatment; 
further significant improvements in mean pain 
intensity scores were observed with continued 
tapentadol PR treatment. In this study, pain 
relief was maintained or improved for patients 
who switched directly from WHO step III opioid 
treatment to tapentadol PR, with the majority 
of patients requiring no dose adjustment to 
reach the minimum target of titration at week 6, 
and treatment discontinuations were relatively 
infrequent. Improvements were also observed in 
patient-rated measures of quality of life, health 
status, and function, including PGIC and CGIC 
ratings, the EQ-5D health status index, SF-36 
scores, and the HADS anxiety and depression 
subscale scores. Patient satisfaction also increased 
substantially upon rotation to tapentadol PR 
treatment. At baseline, all patients rated their 
treatment satisfaction as “fair” or “poor,” and 
after 6 weeks of treatment with tapentadol 
PR, these ratings improved such that 72.5% of 
patients rated their satisfaction as “good,” “very 
good,” or “excellent.” It is also noteworthy that 
satisfaction ratings continued to improve over 
the course of the study (82.8% of patients had 
“good,” “very good,” or “excellent” ratings at 
week 12).
There were some differences observed 
in the history of low back pain between 
the painDETECT negative and unclear/
positive groups. On average, patients in the 
painDETECT unclear/positive subset consulted 
a doctor for their pain earlier and required 
more consultations, analgesic regimens, and 
hospitalizations for their pain than patients in 
the painDETECT negative subset, but patients 
in the painDETECT unclear/positive subset were 
generally off work fewer times for pain during 
the past year than those in the painDETECT 
negative subset. These results should be 
interpreted with caution because employment 
status was not documented in this study; 
therefore, it is possible that the differences 
in the reported impact of pain on time off 
work between the painDETECT negative and 
unclear/positive groups may have been related 
to differences in employment status (i.e., 
unemployed patients would not have reported 
that pain had an impact on time off work).
For patients who reduced or discontinued 
concomitant WHO step I opioids or coanalgesics 
in the tapering substudy, responder rates were 
generally in line with those observed for the 
overall study population. The percentage of 
patients with the same or less pain compared with 
week −1 remained relatively constant following 
the discontinuation of analgesics or coanalgesics 
in the substudy. Similar to the overall study 
population, significant decreases from baseline 
were observed in mean pain intensity scores at 
weeks 6, 8, and 12 for patients participating in 
the tapering substudy. These results indicate that 
these concomitant WHO step I analgesics and 
coanalgesics did not contribute substantially to 
the pain relief achieved during the study, based 
on the maintenance and improvement of pain 
relief with tapentadol alone.
For patients with low back pain with a 
neuropathic pain component (painDETECT 
unclear or positive score at baseline or screening), 
the effects of tapentadol treatment on the 
neuropathic pain component of their low back 
pain were evaluated in further detail. Although 
the painDETECT questionnaire has been recently 
validated for the evaluation of neuropathic 
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pain over time [33], it was not validated when 
this study was conducted [30]. Therefore, the 
validated NPSI [31] was used concomitantly 
to measure changes in neuropathic pain 
symptoms. Both the painDETECT and NPSI 
results showed that on average, patients with a 
neuropathic pain component to their low back 
pain experienced significant improvements in 
symptoms of neuropathic pain. In addition, NPSI 
results showed that the number of pain attacks 
during a 24-h period decreased over the course 
of treatment with tapentadol PR. Results from 
both the current study and a previous study [22] 
of tapentadol PR in patients with severe, chronic 
low back pain with a neuropathic component 
indicate that painDETECT classification can be 
altered with effective treatment. In the previous 
study in patients with severe, chronic low back 
pain, all patients with a neuropathic component 
to their low back pain (a painDETECT unclear 
or positive score) reached a painDETECT 
negative score over the course of treatment with 
tapentadol PR [22]. That study involved patients 
who had not responded to their previous 
therapy of WHO step I or II opioids or no regular 
analgesic treatment [22]. In the current study, 
patients with a painDETECT positive score (>18) 
at baseline achieved an unclear score (<18) and 
patients with a painDETECT unclear score at 
baseline achieved a negative score (<12) over 
the course of treatment with tapentadol PR. This 
study used a selected population of patients who 
had responded to WHO step III opioid therapy 
(as evidenced by NRS-3 scores); patients in this 
study with painDETECT unclear or positive 
scores had achieved pain relief with their prior 
therapy, but still suffered from neuropathic pain 
symptoms that WHO step III opioids did not 
control. Without a washout period, estimations 
of the neuropathic pain component using the 
painDETECT questionnaire and NPSI may have 
been affected by effective prior therapy, which 
may have decreased neuropathic pain symptoms. 
Nevertheless, significant improvements were 
observed in neuropathic pain symptoms 
(based on the NPSI and painDETECT) with 
tapentadol treatment in the current study; 
these improvements are particularly striking 
because the patients in this study had already 
achieved adequate pain relief with their prior 
analgesic regimen. In this study, the NPSI 
referred to pain radiating towards or into the 
leg, which is characteristic of sciatica (one of the 
primary presenting symptoms of lumbosacral 
radiculopathy) [34]. Double-blind studies of 
standard regimens used for neuropathic pain 
(e.g., pregabalin, tricyclic antidepressants, 
opioids) have shown somewhat limited efficacy 
in chronic painful radiculopathy [10]. The 
improvements in neuropathic pain symptoms 
for pain radiating towards or into the leg in 
the current study suggest that tapentadol may 
be useful for the management of pain typically 
associated with radiculopathy [35]. These 
results may reflect the benefit of a combination 
of opioid action and noradrenaline reuptake 
inhibition provided by tapentadol [36].
The tapering of WHO step I analgesics and 
coanalgesics in the substudy from week 9 to 12 
could have led to artificially induced pain peaks 
that would have affected effectiveness, quality 
of life, and function results. For all effectiveness, 
quality of life, and function measures, outcomes 
were consistent when results from weeks 9 
through 12 for patients who participated 
in the tapering substudy were included and 
when these results were excluded, indicating 
that the tapering of WHO step I analgesics or 
coanalgesics in the substudy had no clinically 
relevant impact on the evaluated outcomes.
For patients showing a poor response to an 
opioid analgesic or who experience intolerable 
side effects, opioid switching is often used to 
improve pain relief or tolerability [37, 38]. 
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Determining the appropriate ratio, when 
switching from one opioid analgesic to another, 
is critical for successful conversion, particularly 
for patients who showed a poor response to the 
prior opioid or for those who are switching from 
high doses of opioids [37]. Drug overdose may 
result in intolerable side effects with the new 
opioid analgesic, while underdosing may result 
in the occurrence of withdrawal symptoms.
In a study of patients with chronic, 
nonmalignant pain, the rate of withdrawal was 
32% for patients switching from one PR opioid 
to another and 44% for patients switching 
from an IR opioid to a PR opioid [39]. There 
is a lack of strong evidence related to opioid 
switching, particularly with respect to adequate 
equipotency data [37, 38]. 
The current multicenter, multinational, 
open-label phase 3b study was designed to 
provide evidence for the efficacy and tolerability 
of tapentadol, when switching directly from 
a strong opioid analgesic that provided 
adequate analgesia but poor tolerability. Based 
on the prevalence of AEs reported as the 
underlying reason for switching to tapentadol, 
improvements in tolerability were observed with 
tapentadol PR relative to previous WHO step III 
analgesic regimens. In the current study, 21% 
of patients reported a TEAE of drug withdrawal. 
Although many of these cases may be attributed 
to a site-related effect (because 50% of cases were 
observed at a single study site), this outcome 
may need to be taken into consideration when 
switching patients from strong opioid therapy 
to tapentadol PR. In this study, starting doses 
of tapentadol (which were based on the MEDs 
of the previous WHO step III opioids) were 
approximately 30−75% lower than the calculated 
dose of the previous opioid; given that the doses 
of tapentadol were at least 30% lower than the 
MEDs of previous opioids, the lower µ-opioid 
component of tapentadol compared with prior 
WHO step III opioids may also need to be taken 
into account for equianalgesic conversions in 
patients at risk of developing withdrawal. In the 
higher MED dose ranges, equianalgesic ratios 
decreased in favor of tapentadol, suggesting that 
a low cross-tolerance to classical opioids allowed 
patients to overcome the dose excesses caused 
by tolerance to the previous opioid by rotation 
to tapentadol. This finding is also in line with a 
proposed lower potential for the development of 
tolerance with tapentadol treatment.
There were several limitations to this study. 
The sample size was lower than initially planned 
because of the early termination of the study due 
to slow recruitment; a higher sample size might 
have contributed to a more accurate calculation 
of equianalgesic ratios. This was an effectiveness- 
and practice-oriented open-label study without 
a placebo or active comparator. As described 
previously, screening and baseline painDETECT 
and NPSI results may have been affected by prior 
treatment. Despite any potential limitations, it 
is recognized more and more by the scientific 
community that real-world effectiveness trials 
are of great value, as they are highly related to 
routine clinical practice and avoid the artificial 
settings and patient selection requirements 
that are commonly required for trials driven by 
regulatory guidelines.
CONCLUSIONS
Results of this open-label, phase 3b study 
support those of previous, randomized, double-
blind, controlled, phase 3 studies of tapentadol 
PR for moderate-to-severe, chronic low back 
pain [18] and neuropathic pain (painful diabetic 
peripheral neuropathy) [20]. Overall, results 
indicate that direct rotation from previous WHO 
step III opioid therapy to tapentadol PR could be 
achieved without compromising pain relief in 
a strong opioid responder population, allowing 
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for even further reduction of pain intensity. 
Equianalgesic ratios could be calculated in the 
current study for tapentadol to oxycodone, 
buprenorphine, fentanyl, morphine, and 
hydromorphone; the equianalgesic ratios 
calculated for tapentadol to oxycodone 
were in line with those observed in previous 
randomized, double-blind, placebo- and active-
controlled, phase 3 studies of tapentadol PR for 
chronic pain, in which oxycodone was the main 
comparator [17, 18]. Furthermore, tapentadol 
PR was associated with improvements in health 
status, quality of life, treatment satisfaction, 
function, neuropathic pain symptoms, and 
tolerability relative to prior WHO step III opioid 
analgesics.
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APPENDIX
Table A1  Responder rates 1 and 2 at baseline and at weeks 6 and 12 using observed-case analysis (with and without the 
week 9−12 data for the tapering substudy population) and using the LOCF (without the week 9−12 data for the tapering 
substudy population) – main analysis population
  Observed-case analysis  LOCF
  Week 6 Week 12  Week 6 Week 12
Responder rate, n (%)  With Without  Without
   substudy substudy  substudy
painDETECT negative (n = 37) (n = 34) (n = 28) (n = 45) (n = 39)
Responder rate 1 30 (81.1) 31 (91.2) 25 (89.3) 35 (77.8) 32 (82.1)
Responder rate 2 23 (62.2) 25 (73.5) 20 (71.4) 24 (53.3) 21 (53.8)
painDETECT unclear/positive (n = 65) (n = 59) (n = 42) (n = 76) (n = 59)
Responder rate 1 52 (80.0) 45 (76.3) 31 (73.8) 59 (77.6) 41 (69.5)
Responder rate 2 42 (64.6) 44 (74.6) 30 (71.4) 46 (60.5) 35 (59.3)
Total (n = 102) (n = 93) (n = 70) (n = 121) (n = 98)
Responder rate 1 82 (80.4) 76 (81.7) 56 (80.0) 94 (77.7) 73 (74.5)
Responder rate 2 65 (63.7) 69 (74.2) 50 (71.4) 70 (57.9) 56 (57.1)
LOCF last observation carried forward
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Table A2  Mean (SD) pain intensity scores (11-point NRS-3) at baseline and at weeks 6 and 12 using observed-case analysis 
(with and without the week 9−12 data for the tapering substudy population) and using the LOCF (without the week 9−12 
data for the tapering substudy population) – main analysis population
  Observed-case analysis  LOCF
 Baseline Week 6 Week 12  Week 6 Week 12
Pain intensity   With Without  Without
   substudy substudy  substudy
 (n = 122) (n = 101) (n = 93) (n = 70) (n = 121) (n = 98)
Mean (SD) pain intensity 4.8 (0.75) 4.0 (1.77)* 3.6 (1.97)* 3.8 (1.85)* 4.1 (1.84)* 4.1 (1.89)
LOCF last observation carried forward, NRS-3 numerical rating scale-3, SD standard deviation. * P < 0.05 for the change from baseline
Table A3  Subject satisfaction with treatment ratings at baseline and at weeks 6 and 12 using observed-case analysis (with 
and without the week 9–12 data for the tapering substudy population) and using the LOCF (without the week 9–12 data 
for the tapering substudy population) – main analysis population
  Observed-case analysis  LOCF
 Baseline Week 6 Week 12  Week 6 Week 12
Satisfaction rating, n (%)   With Without  Without
   substudy substudy  substudy
 (n = 123) (n = 102) (n = 93) (n = 70) (n = 121) (n = 98)
Excellent 0 2 (2.0) 2 (2.2) 2 (2.9) 2 (1.7) 2 (2.0)
Very good 0 25 (24.5) 32 (34.4) 22 (31.4) 25 (20.7) 22 (22.4)
Good 0 47 (46.1) 43 (46.2) 34 (48.6) 51 (42.1) 40 (40.8)
Fair 92 (74.8) 21 (20.6) 11 (11.8) 9 (12.9) 30 (24.8) 23 (23.5)
Poor 30 (24.4) 5 (4.9) 4 (4.3) 2 (2.9) 13 (10.7) 11 (11.2)
Missing 1 (0.8) 2 (2.0) 1 (1.1) 1 (1.4) 0 0
LOCF last observation carried forward
Table A4  PGIC and CGIC ratings at baseline and at weeks 6 and 12 using observed-case analysis (with and without the 
week 9–12 data for the tapering substudy population) and using the LOCF (without the week 9–12 data for the tapering 
substudy population) – main analysis population
  Observed-case analysis  LOCF
  Week 6 Week 12  Week 6 Week 12
Rating, n (%)  With Without  Without 
   substudy substudy  substudy
  (n = 102)  (n = 93) (n = 70) (n = 120) (n = 97)
PGIC     
 Very much improved 5 (4.9) 9 (9.7) 5 (7.1) 5 (4.2) 5 (5.2)
 Much improved 29 (28.4) 34 (36.6) 24 (34.3) 30 (25.0) 25 (25.8)
 Minimally improved 47 (46.1) 38 (40.9) 31 (44.3) 48 (40.0) 35 (36.1)
 No change 11 (10.8) 9 (9.7) 8 (11.4) 17 (14.2) 14 (14.4)
 Minimally worse 6 (5.9) 2 (2.2) 1 (1.4) 9 (7.5) 8 (8.2)
 Much worse 3 (2.9) 1 (1.1) 1 (1.4) 10 (8.3) 9 (9.3)
 Very much worse 0 0 0 1 (0.8) 1 (1.0)
 Missing 1 (1.0) 0 0 0 0
CGIC     
 Very much improved 5 (4.9) 11 (11.8) 5 (7.1) 5 (4.2) 5 (5.2)
 Much improved 39 (38.2) 41 (44.1) 31 (44.3) 40 (33.3) 32 (33.0)
 Minimally improved 38 (37.3) 29 (31.2) 24 (34.3) 40 (33.3) 30 (30.9)
 No change 12 (11.8) 8 (8.6) 8 (11.4) 16 (13.3) 14 (14.4)
 Minimally worse 5 (4.9) 3 (3.2) 1 (1.4) 12 (10.0) 9 (9.3)
 Much worse 2 (2.0) 1 (1.1) 1 (1.4) 7 (5.8) 7 (7.2)
 Very much worse 0 0 0 0 0
 Missing 1 (1.0) 0 0 0 0
CGIC clinician global impression of change, LOCF last observation carried forward, PGIC patient global impression of change
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Table A5  Mean (SD) EQ-5D Health Status Index Score at baseline and at weeks 6 and 12 using observed-case analysis (with 
and without the week 9–12 data for the tapering substudy population) and using the LOCF (without the week 9–12 data 
for the tapering substudy population) – main analysis population
  Observed-case analysis  LOCF
 Baseline Week 6 Week 12  Week 6 Week 12
   With Without  Without 
   substudy substudy  substudy
 (n = 120) (n = 101) (n = 92) (n = 70) (n = 118) (n = 95)
EQ-5D health status index score 0.39 (0.307) 0.55 (0.246)* 0.57 (0.252)* 0.57 (0.242)* 0.53 (0.251)* 0.52 (0.255)*
EQ-5D EuroQol-5 Dimension, LOCF last observation carried forward, SD standard deviation 
*P < 0.0001 for the change from baseline
Table A6  Mean (SD) SF-36 scores at baseline and at weeks 6 and 12 using observed-case analysis (with and without the 
week 9–12 data for the tapering substudy population) and using the LOCF (without the week 9–12 data for the tapering 
substudy population) – main analysis population
  Observed-case analysis  LOCF
 Baseline Week 6 Week 12  Week 6 Week 12
Subscale or summary   With Without  Without 
   substudy substudy  substudy
 (n = 120) (n = 99)  (n = 93) (n = 70) (n = 118) (n = 95)
Role - physicala 13.4 (25.17) 21.7 (29.81)* 24.2 (35.25)* 23.9 (35.73)* 18.2 (28.43) 18.4 (32.25)
Physical functioning 33.5 (19.94) 42.4 (21.52)* 43.8 (24.47)* 43.4 (23.18)* 40.3 (21.74)* 40.6 (23.08)*
Bodily painb 28.8 (14.30) 40.3 (16.98)* 42.9 (19.00)* 39.8 (17.83)* 37.8 (17.34)* 36.5 (17.51)*
General healthc 41.3 (20.32) 48.7 (20.92)* 48.1 (22.01)* 48.3 (22.70)* 46.3 (21.15)* 44.5 (22.07)*
Vitality 32.3 (17.75) 42.2 (19.64)* 45.1 (22.66)* 44.0 (22.03)* 40.0 (19.90)* 40.1 (21.49)*
Social functioningb 44.0 (28.30) 52.7 (26.08)* 55.6 (27.68)* 55.0 (25.22)* 48.4 (27.23) 48.9 (26.65)
Role - emotionala 42.6 (44.24) 41.4 (40.44) 56.2 (42.21)* 55.6 (41.10)* 43.2 (41.42) 51.6 (42.05)
Mental health 54.3 (19.32) 60.2 (20.52)* 65.3 (22.76)* 65.3 (22.26)* 58.0 (20.69)* 60.7 (22.15)*
Physical componentb 27.9 (7.07) 32.6 (7.93)* 31.7 (8.83)* 31.3 (8.95)* 31.4 (8.13)* 30.0 (8.54)*
Mental componentb 41.2 (11.97) 43.1 (11.47) 46.7 (12.55)* 46.6 (11.99)* 42.3 (11.46) 44.4 (11.83)*
BL baseline, LOCF last observation carried forward, SD standard deviation, SF-36 Short Form-36, W week
a BL, n = 119; observed-case analysis: W6, n = 99; W12 (with substudy), n = 92; W12 (without substudy), n = 69; LOCF: 
W6, n = 118; W12 (without substudy), n = 95
b BL, n = 120; observed-case analysis: W6, n = 101; W12 (with substudy), n = 93; W12 (without substudy), n = 70; LOCF: 
W6, n = 118; W12 (without substudy), n = 95
c BL, n = 120; observed-case analysis: W6, n = 100; W12 (with substudy), n = 93; W12 (without substudy), n = 70; LOCF: 
W6, n = 118; W12 (without substudy), n = 95
* P < 0.05 for the change from baseline
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Table A7  Mean (SD) HADS anxiety and depression subscale scores at baseline and at weeks 6 and 12 using observed-case 
analysis (with and without the week 9–12 data for the tapering substudy population) and using the LOCF (without the 
week 9–12 data for the tapering substudy population) – main analysis population
   Observed-case analysis  LOCF
  Baseline Week 6 Week 12  Week 6 Week 12
Subscale    With Without  Without
    substudy substudy  substudy
painDETECT negative (n = 45) (n = 35) (n = 34) (n = 28) (n = 44) (n = 38)
 Anxiety subscale 5.9 (4.21) 5.1 (3.69) 3.8 (3.26)* 3.8 (3.30)* 5.4 (3.92) 4.5 (3.78)*
 Depression subscale 6.2 (4.40) 4.8 (3.46) 4.6 (3.42)* 4.6 (3.33) 5.7 (4.04) 5.7 (4.04)
painDETECT unclear/positive (n = 73) (n = 64) (n = 59) (n = 42) (n = 73) (n = 56)
 Anxiety subscale 8.5 (3.96) 7.3 (4.02)* 7.1 (4.01)* 6.9 (4.12)* 7.5 (4.08)* 7.3 (4.13)*
 Depression subscale 8.9 (4.33) 8.0 (4.14)* 8.1 (4.67) 7.9 (4.36) 8.4 (4.30)* 8.5 (4.39)
Total (n = 118) (n = 99) (n = 93) (n = 70) (n = 117) (n = 94)
 Anxiety subscale 7.5 (4.23) 6.5 (4.03)* 5.9 (4.06)* 5.7 (4.09)* 6.7 (4.13)* 6.1 (4.20)*
 Depression subscale 7.9 (4.54) 6.8 (4.17)* 6.8 (4.57)* 6.6 (4.28)* 7.4 (4.38)* 7.3 (4.45)
HADS Hospital Anxiety and Depression Scale, LOCF last observation carried forward, SD standard deviation
* P < 0.05 for the change from baseline
Table A8  NPSI results in the baseline painDETECT unclear/positive subset: (a) mean (SD) NPSI overall feeling and 
subscores, (b) total number of pain attacks within the past 24 h (with and without the tapering substudy population) and 
using the LOCF (without the tapering substudy population) – main analysis population
a) Overall feeling and subscores
  Observed-case analysis  LOCF
 Baseline Week 6 Week 12  Week 6 Week 12
   With Without  Without
   substudy  substudy  substudy
Mean (SD) NPSI score (n = 71) (n = 61) (n = 56) (n = 39) (n = 72) (n = 55)
Overall feeling scorea 0.41 (0.158) 0.30 (0.178)* 0.28 (0.211)* 0.32 (0.217)* 0.30 (0.177)* 0.32 (0.196)*
Burning pain subscore 0.41 (0.284) 0.32 (0.273)* 0.27 (0.281)* 0.30 (0.291)* 0.33 (0.259)* 0.32 (0.267)*
Pressing pain subscorea 0.41 (0.230) 0.32 (0.229)* 0.30 (0.235)* 0.34 (0.239) 0.31 (0.228)* 0.33 (0.232)*
Paroxysmal pain subscore 0.42 (0.221) 0.27 (0.231)* 0.25 (0.255)* 0.30 (0.264)* 0.28 (0.240)* 0.30 (0.258)*
Evoked pain subscore 0.39 (0.216) 0.27 (0.212)* 0.27 (0.252)* 0.33 (0.268) 0.28 (0.206)* 0.32 (0.243)
Paresthesia/dysesthesia  
subscore 0.42 (0.233) 0.30 (0.210)* 0.30 (0.239)* 0.32 (0.237)* 0.33 (0.225)* 0.34 (0.252)*
b) Number of pain attacks
  Observed-case analysis  LOCF
 Baseline Week 6 Week 12  Week 6 Week 12
   With Without  Without
Number of pain attacks   substudy substudy  substudy 
during the past 24 h, n (%) (n = 76) (n = 65) (n = 59) (n = 42) (n = 74) (n = 57)
>20 attacks 6 (7.9) 5 (7.7) 4 (6.8) 3 (7.1) 7 (9.5) 5 (8.8)
11–20 attacks 10 (13.2) 10 (15.4) 7 (11.9) 4 (9.5) 12 (16.2) 8 (14.0)
6–10 attacks 19 (25.0) 12 (18.5) 11 (18.6) 9 (21.4) 14 (18.9) 11 (19.3)
1–5 attacks 28 (36.8) 20 (30.8) 14 (23.7) 12 (28.6) 23 (31.1) 15 (26.3)
No attacks 8 (10.5) 14 (21.5) 20 (33.9) 11 (26.2) 16 (21.6) 16 (28.1)
Missing 5 (6.6) 4 (6.2) 3 (5.1) 3 (7.1) 2 (2.7) 2 (3.5)
BL baseline, LOCF last observation carried forward, NPSI Neuropathic Pain Symptom Inventory, SD standard deviation, 
W week
a BL, n = 69; observed-case analysis: W6, n = 60; W12 (with substudy), n = 56; W12 (without substudy), n = 39; LOCF: 
W6, n = 72; W12 (without substudy), n = 55
* P < 0.05 for the change from baseline
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